Maze Therapeutics (NASDAQ:MAZE) CEO Sells $181,532.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 6,982 shares of Maze Therapeutics stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $26.00, for a total value of $181,532.00. Following the completion of the transaction, the chief executive officer owned 28,523 shares of the company’s stock, valued at $741,598. The trade was a 19.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Stock Down 1.1%

Shares of MAZE traded down $0.30 during midday trading on Wednesday, hitting $26.05. The company had a trading volume of 401,776 shares, compared to its average volume of 709,447. The company’s 50-day simple moving average is $30.19 and its 200-day simple moving average is $37.63. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88. The firm has a market capitalization of $1.44 billion, a P/E ratio of -10.30 and a beta of 2.50. Maze Therapeutics, Inc. has a 1 year low of $9.73 and a 1 year high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The firm had revenue of $20.00 million during the quarter. As a group, sell-side analysts expect that Maze Therapeutics, Inc. will post -2.74 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on MAZE. Mizuho upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 11th. BTIG Research reiterated a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research note on Wednesday, March 25th. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. HC Wainwright boosted their target price on Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. Finally, Truist Financial decreased their target price on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a research note on Tuesday, April 14th. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Maze Therapeutics has an average rating of “Buy” and an average price target of $66.00.

Institutional Investors Weigh In On Maze Therapeutics

Several institutional investors have recently added to or reduced their stakes in MAZE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Maze Therapeutics during the first quarter worth approximately $57,000. Goldman Sachs Group Inc. purchased a new stake in Maze Therapeutics during the first quarter worth approximately $145,000. Rhumbline Advisers acquired a new position in Maze Therapeutics during the first quarter worth approximately $80,000. Geode Capital Management LLC increased its position in Maze Therapeutics by 8.8% during the second quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock worth $2,838,000 after buying an additional 18,773 shares during the period. Finally, Legal & General Group Plc increased its position in Maze Therapeutics by 387.0% during the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after buying an additional 3,371 shares during the period.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.